Association between EGF promoter polymorphisms and cancer risk: A meta-analysis

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1389-1397

  Xu, Wei ^a   Li, Yan ^a   Wang, Xueli ^a   Chen, Bo ^a   Liu, Shan ^a   Wang, Yan ^a   Zhao, Weihong ^a   Wu, Jianqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; Epidermal growth factor; Meta analysis; Polymorphism; Susceptibility

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ALLELE; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CORRELATION ANALYSIS; ESOPHAGUS CANCER; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GLIOMA; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; MEDICAL LITERATURE; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; RISK ASSESSMENT; STOMACH CANCER; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; EPIDERMAL GROWTH FACTOR; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; SURVIVAL RATE;

EID: 78650036984     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9392-8     Document Type: Article

References (50)

1. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal. 2006;18:2089-97. (Pubitemid 44642342)
2. Salomon DS, Brandt R, Ciardiello F, Normanno NE. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
3. Fenton SE, Groce NS, Lee DC. Characterization of the mouse epidermal growth factor promoter and 5'-flanking region. Role for an atypical TATA sequence. J Biol Chem. 1996;271:30870-8.
4. Price PM, Megyesi J, Saggi S, Safirstein RL. Regulation of transcription by the rat EGF gene promoter in normal and ischemic murine kidney cells. Am J Physiol. 1995;268: F664-70.
5. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008;299:53-60.
6. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002;359:397-401. (Pubitemid 34158948)
7. Araujo AP, Ribeiro R, Pinto D, Pereira D, Sousa B, Mauricio J, et al. Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease. DNA Cell Biol. 2009;28:265-9.
8. Wang Y, Tian T, Hu Z, Tang J, Wang S, Wang X, et al. EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. Breast Cancer Res Treat. 2008;111:321-7.
9. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res. 2008;14:3216-22.
10. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 2004;64:1220-3. (Pubitemid 38235584)
11. Casula M, Alaibac M, Pizzichetta MA, Bono R, Ascierto PA, Stanganelli I, Canzanella S, Palomba G, Zattra E, Italian Melanoma Intergroup (IMI), Palmieri G. Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatol. 2009. doi:10.1186/1471-5945-9-7.
12. Okamoto I, Roka F, Krogler J, Endler G, Kaufmann S, Tockner S, et al. The EGF A61G polymorphism is associated with diseasefree period and survival in malignant melanoma. J Invest Dermatol. 2006;126:2242-6. (Pubitemid 44413171)
13. Randerson-Moor JA, Gaut R, Turner F, Whitaker L, Barrett JH, Silva Idos S, et al. The relationship between the epidermal growth factor (EGF) 5' UTR variant A61G and melanoma/nevus susceptibility. J Invest Dermatol. 2004;123:755-9. (Pubitemid 39281617)
14. Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res. 2004;64:2668-72. (Pubitemid 38500598)
15. McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer. 2003;107:673-5. (Pubitemid 37296132)
16. James MR, Hayward NK, Dumenil T, Montgomery GW, Martin NG, Duffy DL. Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia. J Invest Dermatol. 2004;123:760-2. (Pubitemid 39281618)
17. Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, et al. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet. 2007;172:33-7. (Pubitemid 44920265)
18. Liu X, Li L, Chen X, Wang X, Mu L, Li Y, et al. No association between EGF +61 A/G polymorphism and increased risk of glioma. Int J Biol Markers. 2009;24:77-82.
19. Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res. 2007;13:2621-6. (Pubitemid 46788028)
20. Cheung WY, Zhai R, Kulke MH, Heist RS, Asomaning K, Ma C, et al. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk. Carcinogenesis. 2009;30:1363-7.
21. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer. Oncol Res. 2008;17:167-74.
22. Cui L, Pan XM, Ma CF, Shang-Guan J, Yu HB, Chen GX, Wang J. Association between epidermal growth factor polymorphism and esophageal squamous cell carcinoma susceptibility. Dig Dis Sci. 2009. doi:10.1007/s10620-008-0700-5.
23. Hamai Y, Matsumura S, Matsusaki K, Kitadai Y, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology. 2005;72:133-8. (Pubitemid 40674996)
24. Goto Y, Ando T, Goto H, Hamajima N. No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2454-6. (Pubitemid 41437852)
25. Jin G, Miao R, Deng Y, Hu Z, Zhou Y, Tan Y, et al. Variant genotypes and haplotypes of the epidermal growth factor gene promoter are associated with a decreased risk of gastric cancer in a high-risk Chinese population. Cancer Sci. 2007;98:864-8. (Pubitemid 46691824)
26. Spindler KL, Nielsen JN, Ornskov D, Brandslund I, Jakobsen A. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol. 2007;46:1113-7. (Pubitemid 350058877)
27. Wu GY, Hasenberg T, Magdeburg R, Bonninghoff R, Sturm JW, M Keese. Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg. 2009;33:124-9.
28. Qi P, Chen YM, Gao CF, Fang M, Sun XJ, Liu Y. Relationship between polymorphism of epidermal growth factor 5' UTR variant g61a gene and hepatocellular carcinoma in patients with chronic hepatitis b virus infection in China. Chinese J Biol. 2008;21:1051-3. Chinese.
29. Vishnoi M, Pandey SN, Modi DR, Kumar A, Mittal B. Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1-509C>T gene polymorphisms with gallbladder cancer. Hum Immunol. 2008;69:360-7.
30. Muslimov GF. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bull Exp Biol Med. 2008;145:535-8.
31. Kang HG, Choi JE, Lee WK, Kam S, Cha SI, Kim CH, et al. +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology. 2007;12:902-5. (Pubitemid 350045717)
32. Lim YJ, Kim JW, Song JY, Hong MS, Jin SY, Yoon SH, et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett. 2005;374(3):157-60. (Pubitemid 40128286)
33. Gao LB, Wei YS, Zhou B, Wang YY, Liang WB, Li C, et al. No association between epidermal growth factor and epidermal growth factor receptor polymorphisms and nasopharyngeal carcinoma. Cancer Genet Cytogenet. 2008;185:69-73.
34. Einarsdottir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, et al. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res. 2008;10: R15.
35. Jain M, Kumar S, Upadhyay R, Lal P, Tiwari A, Ghoshal UC, et al. Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther. 2007;6:1553-8. (Pubitemid 351590326)
36. Kang S, Kim JW, Park NH, Song YS, Park SY, Kang SB, et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer. 2007;17:492-6. (Pubitemid 46426784)
37. Einarsdottir K, Darabi H, Czene K, Li Y, Low YL, Li YQ, et al. Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival. Br J Cancer. 2009;100:1358-64.
38. Araujo AP, Ribeiro R, Pereira D, Pinto D, Sousa B, Catarino R, et al. Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene. Exp Biol Med (Maywood). 2009;234:241-5.
39. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:972-7. (Pubitemid 351536431)
40. Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, et al. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res. 2008;14:3367-71.
41. Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9:341-6.
42. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
43. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
44. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
45. Tobias A. Assessing the influence of a single study in the metaanalysis estimate. Stata Technical Bulletin. 1999;47(sbe26): 15-7.
46. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629-34. (Pubitemid 27387172)
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
48. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003;95:851-67. (Pubitemid 36833877)
49. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007;19:2013-23. (Pubitemid 47353811)
50. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003;10:1-21. (Pubitemid 36457237)